|
1.
|
Hilfiker A, Hilfiker-Kleiner D, Pannuti A
and Lucchesi JC: mof, a putative acetyl transferase gene related to
the Tip60 and MOZ human genes and to the SAS genes of yeast, is
required for dosage compensation in Drosophila. EMBO J.
16:2054–2060. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Smith ER, Cayrou C, Huang R, Lane WS, Côtê
J and Lucchesi JC: A human protein complex homologous to the
Drosophila MSL complex is responsible for the majority of histone
H4 acetylation at lysine 16. Mol Cell Biol. 25:9175–9188. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Mendjan S, Taipale M, Kind J, Holz H,
Gebhardt P, Schelder M, Vermeulen M, Buscaino A, Duncan K, Mueller
J, Wilm M, Stunnenberg HG, Saumweber H and Akhtar A: Nuclear pore
components are involved in the transcriptional regulation of dosage
compensation in Drosophila. Mol Cell. 21:811–823. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Cai Y, Jin J, Swanson SK, Cole MD, Choi
SH, Florens L, Washburn MP, Conaway JW and Conaway RC: Subunit
composition and substrate specificity of a MOF-containing histone
acetyltransferase distinct from the male-specific lethal (MSL)
complex. J Biol Chem. 285:4268–4272. 2010. View Article : Google Scholar
|
|
5.
|
Carrozza MJ, Utley RT, Workman JL and Côté
J: The diverse functions of histone acetyltransferase complexes.
Trends Genet. 19:321–329. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Gupta A, Guerin-Peyrou TG, Sharma GG, Park
C, Agarwal M, Ganju RK, Pandita S, Choi K, Sukumar S, Pandita RK,
Ludwig T and Pandita TK: The mammalian ortholog of Drosophla
MOF that acetylates histone H4 lysine 16 is essential for
embryogenesis and oncogenesis. Mol Cell Biol. 28:397–409. 2008.
|
|
7.
|
Sharma GG, So S, Gupta A, Kumar R, Cayrou
C, Avvakumov N, Bhadra U, Pandita RK, Porteus MH, Chen DJ, Cote J
and Pandita TK: MOF and histone H4 acetylation at lysine 16 are
critical for DNA damage response and double-strand break repair.
Mol Cell Biol. 30:3582–3595. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Rea S, Xouri G and Akhtar A: Males absent
on the first (MOF): from flies to humans. Oncogene. 26:5385–5394.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Taipale M, Rea S, Richter K, Vilar A,
Lichter P, Imhof A and Akhtar A: hMOF histone acetyltransferase is
required for histone H4 lysine 16 acetylation in mammalian cells.
Mol Cell Biol. 25:6798–6810. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
11.
|
Schwab LP, Peacock DL, Majumdar D, Ingels
JF, Jensen LC, Smish KD, Cushing RC and Seagroves TN:
Hypoxia-inducible factor 1α promotes primary tumor growth and
tumor-initiating cell activity in breast cancer. Breast Cancer Res.
14:R62012.
|
|
12.
|
McDonald PC, Winum JY, Supuran CT and
Dedhar S: Recent developments in targeting carbonic anhydrase IX
for cancer therapeutics. Oncotarget. 3:84–97. 2012.PubMed/NCBI
|
|
13.
|
Law AY and Wong CK: Stanniocalcin-2 is a
HIF-1 target gene that promotes cell proliferation in hypoxia. Exp
Cell Res. 316:466–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Choschzick M, Oosterwijk E, Müller V,
Woelber L, Simon R, Moch H and Tennstedt P: Overexpression of
carbonic anhydrase IX (CAIX) is an independent unfavorable
prognostic marker in endometrioid ovarian cancer. Virchows Arch.
459:193–200. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Seeber LM, Horrée N, Vooijs MA, Heintz AP,
van der Wall E, Verheijen RH and van Diest PJ: The role of hypoxia
inducible factor-1alpha in gynecological cancer. Crit Rev Oncol
Hematol. 78:173–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Elsheikh SE, Green AR, Rakha EA, Powe DG,
Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA,
Grainge MJ, Ball GR, Abdelghany MK, Martinez-Pomares L, Heery DM
and Ellis IO: Global histone modifications in breast cancer
correlate with tumor phenotypes, prognostic factors, and patient
outcome. Cancer Res. 69:3802–3809. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Pfister S, Rea S, Taipale M, Mendrzyk F,
Straub B, Ittrich C, Thuerigen O, Sinn HP, Akhtar A and Lichter P:
The histone acetyltransferase hMOF is frequently downregulated in
primary breast carcinoma and medulloblastoma and constitutes a
biomarker for clinical outcome in medulloblastoma. Int J Cancer.
122:1207–1213. 2008. View Article : Google Scholar
|
|
18.
|
Kulski JK and Dawkins RL: The P5 multicopy
gene family in the MHC is related in sequence to human endogenous
retroviruses HERV-L and HERV-16. Immunogenetics. 49:404–412. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Salih HR and Nüssler V: Commentary: Immune
escape versus tumor tolerance: how do tumors evade immune
surveillance? Eur J Med Res. 6:323–332. 2001.PubMed/NCBI
|
|
20.
|
Kübler K, Arndt PF, Wardelmann E, Landwehr
C, Krebs D, Kuhn W and van der Ven K: Genetic alterations of
HLA-class II in ovarian cancer. Int J Cancer. 123:1350–1356.
2008.PubMed/NCBI
|
|
21.
|
Wang Y, Zhang R, Wu D, Lu Z, Sun W, Cai Y,
Wang C and Jin J: Epigenetic change in kidney tumor: downregulation
of histone acetyltransferase MYST1 in human renal cell carcinoma. J
Exp Clin Cancer Res. 32:82013. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Seeber LM and van Diest PJ: Epigenetics in
ovarian cancer. Methods Mol Biol. 863:253–269. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Asadollahi R, Hyde CA and Zhong XY:
Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol
Oncol. 118:81–87. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Balch C, Matei DE, Huang TH and Nephew KP:
Role of epigenomics in ovarian and endometrial cancers.
Epigenomics. 2:419–447. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Song JS, Chun SM, Lee JY, Kim DK, Kim YH
and Jang SJ: The histone acetyltransferase hMOF is overexpressed in
non-small cell lung carcinoma. Korean J Pathol. 45:386–396. 2011.
View Article : Google Scholar
|
